Literature DB >> 15933057

Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo.

Mark A Little1, C Lucy Smyth, Rashmi Yadav, Lyn Ambrose, H Terence Cook, Sussan Nourshargh, Charles D Pusey.   

Abstract

Systemic small vessel vasculitis is associated with antineutrophil cytoplasm antibodies (ANCAs). While there is mounting in vitro evidence to suggest that ANCAs are capable of enhancing leukocyte-endothelial interactions, no in vivo evidence for this has been provided. In this study a novel rat model of ANCA-associated experimental autoimmune vasculitis (EAV), induced by immunization with human myeloperoxidase (MPO), was used to analyze directly the potential effect of ANCAs on leukocyte-venular wall interactions in vivo as observed by intravital microscopy. These rats developed anti-MPO antibodies directed against rat leukocytes, showed pathologic evidence of small vessel vasculitis, and had enhanced leukocyte adhesion and transmigration in response to the chemokine Groalpha (CXCL1 [CXC ligand 1]). Passive transfer of immunoglobulin from rats with EAV to naive rats conferred enhanced adhesion and transmigration responses in the recipients. Furthermore, rats with EAV and recipients of ANCA-positive immunoglobulin developed extensive microvascular injury, as manifested by mesenteric hemorrhage, in response to CXCL1. This study provides the first direct in vivo evidence for the ability of ANCAs to enhance leukocyte-endothelial interactions and cause microvascular hemorrhage, thereby providing a mechanism by which ANCAs could exert pathogenic effects in systemic vasculitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15933057     DOI: 10.1182/blood-2005-03-0921

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  84 in total

Review 1.  Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Min Chen; Ying Gao; Xiao-Hui Guo; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

3.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

5.  Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo.

Authors:  Sarah L Nolan; Neena Kalia; Gerard B Nash; Dia Kamel; Peter Heeringa; Caroline O S Savage
Journal:  J Am Soc Nephrol       Date:  2008-02-27       Impact factor: 10.121

6.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 7.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 8.  [New pathogenetic aspects in primary systemic vasculitides].

Authors:  P Lamprecht
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

9.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.

Authors:  Adrian Schreiber; Hong Xiao; J Charles Jennette; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

10.  Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis.

Authors:  V C Primo; S Marusic; C C Franklin; W H Goldmann; C G Achaval; R N Smith; M A Arnaout; B Nikolic
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.